Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Bois-Guillaume – page 53

671 clinical trials in Bois-Guillaume, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bois-Guillaume at a glance
671
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

671 trials in Bois-Guillaume

Open in trial search

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Diffuse large B-cell lymphoma

Not recruiting

Study on Lenalidomide, Tafasitamab, and Rituximab for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Non-small cell lung cancer+1

Not recruiting

Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Anal squamous cell carcinoma

Not recruiting

Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondation Franc.Cancerologie Digestive

Monkeypox

Not recruiting

Study on Monkeypox Virus Disease: Effects of Tecovirimat in Patients with and without Antiviral Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tecovirimat
  • Sponsor:University Of Oxford

Hepatic cancer

Not recruiting

Study on Adding Ipilimumab to Atezolizumab and Bevacizumab for Patients with Liver Cancer Receiving First-Line Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Dementia Alzheimer's type

Not recruiting

Study on the Effects of JNJ-63733657 and Florquinitau F18 in Patients with Early Alzheimer's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Janssen Cilag International

T-cell lymphoma

Not recruiting

Study of Tolinapant with Decitabine and Cedazuridine for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Taiho Oncology Inc.

Relapsing-remitting multiple sclerosis

Not recruiting

Study Comparing Rituximab and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Hepatitis D

Not recruiting

Study on Bulevirtide Treatment for Patients with Chronic Hepatitis D

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Gilead Sciences Inc.

Non-small cell lung cancer stage I+1

Not recruiting

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Dermatitis atopic

Not recruiting

Study on Dupilumab Step-Down Strategy for Maintaining Remission in Adults and Adolescents with Atopic Dermatitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clobetasol
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Bois-Guillaume

What the registry says about research in the country

01 Kidney Disease & Transplantation

Innovative research focusing on chronic kidney disease treatments and transplant outcomes, including studies of novel medications like baxdrostat and tegoprubart for improving patient care.

  • Kidney Transplant Rejection Prevention
  • CKD Management
  • Hypertension Control

Multiple trials evaluating new therapeutic approaches for transplant recipients and CKD patients.

02 Blood Disorders

Clinical investigations into treatments for various blood-related conditions, with emphasis on immune thrombocytopenia and thrombotic disorders.

  • Thrombotic Thrombocytopenic Purpura
  • Hemolytic Uremic Syndrome
  • Immunological Therapies

Advanced studies combining established and experimental treatments for better patient outcomes.

03 Infectious Disease Management

Research examining treatment strategies for viral infections and optimization of antibiotic therapy, particularly in elderly populations.

  • Cytomegalovirus Treatment
  • Antibiotic Management
  • Viral Pneumonia

Studies focused on improving treatment protocols and reducing antibiotic overuse.

04 Autoimmune Conditions

Investigation of novel therapies for vasculitis and related autoimmune disorders, including targeted biological treatments.

  • Takayasu Arteritis
  • ANCA-Associated Vasculitis
  • Goodpasture Disease

Evaluating new treatment combinations to improve disease management and patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.